GMAB250117C30000
- 0.10
- 0.000.00%
Genmab Newsroom
Grant of Restricted Stock Units and Warrants to Employees in Genmab
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
Strong Sales and Robust Pipeline Reinforce Genmab's Buy Rating
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
Is Genmab (GMAB) the High Growth International Stock to Invest in Now?
Express News | Genmab Shares Are Trading Lower. The Company Reported FY24 Net Sales for Darzalex
Genmab Announced That Worldwide Net Trade Sales Of Darzalex (Daratumumab), Including Sales Of The Subcutaneous Product (Daratumumab And Hyaluronidase-fihj, Sold Under The Tradename Darzalex Faspro In The U.S.), As Reported By J&J Were $11,670M In 2024
Genmab Announces Net Sales of DARZALEX (Daratumumab) for 2024
TD Cowen Keeps Their Hold Rating on Genmab (GMAB)
Top Gap Ups and Downs on Wednesday: IONQ, BCS, GS and More
Zai Lab to Seek China Approval for Cervical Cancer Therapy After Positive Trial Data
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know
Are Investors Undervaluing Genmab (GMAB) Right Now?
Genmab A/S (0MGB) Receives a Buy From UBS
Barclays Sticks to Its Buy Rating for Genmab A/S (0MGB)
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
HC Wainwright & Co. Maintains Buy on Genmab, Maintains $50 Price Target
Genmab Analyst Ratings
TD Cowen Maintains Genmab(GMAB.US) With Hold Rating
TD Cowen Sticks to Their Hold Rating for Genmab (GMAB)